Veraxa Biotech Holding AG (VRXA)
$1.11-7.50%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $157M
- Beta
- 0.26
- Short % float
- 1.86%
- Days to cover
- 4.6
- SI change
- +12.1%
- 1W
- -7.50%
- 1M
- -26.97%
- vs SPY 1W
- -6.52%
- vs SPY 1M
- -28.84%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-
---
[VALUATION]
P/E TTM-
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-
P/FCF-
EV/EBITDA-
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO-
ND/EBITDA-
BETA0.26
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
Backtest data unavailable.
[REGIME]FULL HISTORY
UNKNOWN
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on VRXA?
- LOPJLB’s latest quantitative signal on Veraxa Biotech Holding AG (VRXA) is SELL. Signals are updated daily.
- What market regime is VRXA in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Veraxa Biotech Holding AG (VRXA) do?
- Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, wit…